CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 28 enrolled
Drug / intervention
Anastrozole +2 moredrug
Likely dose
Anastrozole 1 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00612560
NCT00612560N/ACompleted

Flaxseed vs. Aromatase Inhibitors: Breast Tumor Characteristics and Prognosis

Roswell Park Cancer Institute·interventional·Posted Feb 11, 2008·Updated Oct 12, 2017

In Brief

A clinical study evaluating Anastrozole, flaxseed, and 1 other intervention for Breast Cancer. Completed, enrolled 28 participants across 1 site.

Detailed Summary

The proposed study plans to examine the effect of flaxseed consumption, a phytoestrogen rich food, compared to aromatase inhibitors as a complementary approach to treating estrogen receptor positive breast cancer, as well as the effect of combined flaxseed and aromatase inhibitor therapy on breast cancer treatment. Because of the increasing use of both complementary and alternative approaches to treatment, and the use of aromatase inhibitors in the treatment of breast cancer, the proposed study has potential to provide important clinical information about the effect of foods high in phytoestrogens on a common endocrine therapy used in breast cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 11, 2008
Enrollment StartNov 1, 2007
Primary CompletionJan 1, 2011
Study CompletionApr 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 18.4 years ago

Interventions

Anastrozoledrug

1 mg per day

flaxseeddietary

25 g per day ground

Placebodrug

Placebo pill 1 per day